HybridSPE®-Phospholipid
SUPELCO/55261-U - Cartridge, bed wt. 30 mg, volume 1 mL, pk of 100
Synonym: HybridSPE (phospholipid and protein removal) SPE cartridge tube, 1 mL
Product Type: Equipment/Book
No Accumulation of Phospholipids Using HybridSPE-PL
Lewis Acid Base Interaction Between HybridSPE Zirconia Ions & Phospholipids
HybridSPE-PL 1 mL Cartridge Schematics
| composition | bed wt., 30 mg |
| material | PE frit (20 μm) |
| polypropylene hardware | |
| matrix active group | zirconia-based phase |
| packaging | pk of 100 |
| product line | HybridSPE® |
| Quality Level | 100  |
| technique(s) | solid phase extraction (SPE): suitable |
| volume | 1 mL |
| Application: |
|
| Features and Benefits: | • For use in conjunction with off-line protein precipitation. |
| Features and Benefits: | • Merges the simplicity of protein precipitation and the selectivity of SPE via the targeted removal of phospholipids • Reduce ion-suppression through the complete removal of phospholipids and precipitated proteins • 2-3 step generic procedure • Minimal to no method development • Available in 96-well and 1 mL cartridge dimensions |
| General description: | HybridSPE-Phospholipid technology is a simple and generic sample prep platform designed for the gross level removal of endogenous protein and phospholipid interferences from biological plasma and serum prior to LC-MS or LC-MS/MS analysis. Biological plasma or serum is first subjected to protein precipitation via the addition and mixing of acidified acetonitrile. Precipitated proteins are then removed by centrifugation and the resulting supernatant is loaded on the HybridSPE-Phospholipid 96-well plate or cartridge which acts as a chemical filter that specifically targets the removal of endogenous sample phospholipids. The phospholipid retention mechanism is based on a highly selective Lewis acid-base interaction between the proprietary zirconia ions functionally bonded to the HybridSPE-Phospholipid stationary phase and the phosphate moiety consistent with all phospholipids. The resulting eluent is ready for immediate LC-MS or LC-MS-MS analysis. The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method. |
| Legal Information: | HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany |
).| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41115712 |